Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.
作者信息
Shimabukuro Tom T, Cole Matthew, Su John R
机构信息
Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
出版信息
JAMA. 2021 Mar 16;325(11):1101-1102. doi: 10.1001/jama.2021.1967.
Abstract
摘要
相似文献
1
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.2020年12月14日至2021年1月18日美国接种mRNA新冠疫苗后发生过敏反应的报告
JAMA. 2021 Mar 16;325(11):1101-1102. doi: 10.1001/jama.2021.1967.
2
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.美国 2020 年 12 月 21 日-2021 年 1 月 10 日期间，在接种 Moderna COVID-19 疫苗第一针后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. doi: 10.15585/mmwr.mm7004e1.
3
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.美国 2020 年 12 月 14 日至 23 日：在接种第一剂辉瑞-BioNTech COVID-19 疫苗后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.
4
Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.2020年12月21日至2021年1月10日美国接种第一剂莫德纳新冠疫苗后的过敏反应，包括过敏反应
Am J Transplant. 2021 Mar;21(3):1326-1331. doi: 10.1111/ajt.16517.
5
Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.2020年12月14日至23日美国接种首剂辉瑞-生物科技公司新冠病毒疫苗后发生的过敏反应，包括过敏反应。
Am J Transplant. 2021 Mar;21(3):1332-1337. doi: 10.1111/ajt.16516.
6
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.接种辉瑞-生物科技公司新冠疫苗第一剂后包括过敏反应在内的过敏反应。
JAMA. 2021 Feb 23;325(8):780-781. doi: 10.1001/jama.2021.0600.
7
Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States.美国2019冠状病毒病信使核糖核酸疫苗接种后过敏反应的不成比例性分析
Ann Allergy Asthma Immunol. 2021 Jul;127(1):139-140. doi: 10.1016/j.anai.2021.04.004. Epub 2021 Apr 8.
8
COVID vaccines and safety: what the research says.新冠疫苗与安全性：研究结果
Nature. 2021 Feb;590(7847):538-540. doi: 10.1038/d41586-021-00290-x.
9
First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.2020 年 12 月 14 日至 2021 年 1 月 13 日，COVID-19 疫苗安全监测第一个月-美国。
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):283-288. doi: 10.15585/mmwr.mm7008e3.
10
Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.日本报告的首例接种 mRNA COVID-19 疫苗（辉瑞-生物科技）后发生过敏反应的累积不良事件
**注意**：这是一个基于给定英文文本的机器翻译结果，可能存在不准确或不自然的表达方式。在实际使用中，建议对翻译结果进行进一步的编辑和校对，以确保语言质量和准确性。
Drug Saf. 2021 Nov;44(11):1209-1214. doi: 10.1007/s40264-021-01104-9. Epub 2021 Aug 4.
引用本文的文献
1
Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study.既往有过敏反应的患者接种新冠病毒疫苗加强针的安全性：一项回顾性研究
Trop Dis Travel Med Vaccines. 2025 Aug 14;11(1):30. doi: 10.1186/s40794-025-00266-z.
2
Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.2019冠状病毒病疫苗接种对癌症患者的影响：安全性、有效性及长期影响
Support Care Cancer. 2025 Aug 4;33(8):753. doi: 10.1007/s00520-025-09783-1.
3
The Application of Single-Cell Technologies for Vaccine Development Against Viral Infections.单细胞技术在抗病毒感染疫苗研发中的应用
Vaccines (Basel). 2025 Jun 26;13(7):687. doi: 10.3390/vaccines13070687.
4
Nanotechnology Approaches for Mitigating Biologic Immunogenicity: A Literature Review.减轻生物免疫原性的纳米技术方法：文献综述
Pharmaceutics. 2025 Jul 7;17(7):888. doi: 10.3390/pharmaceutics17070888.
5
National Pharmacovigilance Assessment of Oral Adverse Events Following COVID-19 Vaccination in Germany (2020-2023).德国2020 - 2023年新冠疫苗接种后口腔不良事件的国家药物警戒评估
Int Dent J. 2025 Jul 19;75(5):100906. doi: 10.1016/j.identj.2025.100906.
6
The Future of mRNA Vaccines: Potential Beyond COVID-19.信使核糖核酸疫苗的未来：超越新冠病毒的潜力
Cureus. 2025 May 21;17(5):e84529. doi: 10.7759/cureus.84529. eCollection 2025 May.
7
Enhancing RNA vaccine safety through localized delivery strategies.通过局部递送策略提高RNA疫苗安全性。
Vaccine Insights. 2025 Mar;4(2):41-45. Epub 2025 Mar 20.
8
The Application of mRNA Technology for Vaccine Production-Current State of Knowledge.mRNA技术在疫苗生产中的应用——当前知识状况
Vaccines (Basel). 2025 Apr 4;13(4):389. doi: 10.3390/vaccines13040389.
9
COVID-19 mRNA-1273 vaccination induced mast cell activation with strongly elevated Th cytokines in a systemic mastocytosis patient.在一名系统性肥大细胞增多症患者中，COVID-19 mRNA-1273疫苗接种诱导肥大细胞活化，并伴有Th细胞因子显著升高。
Inflamm Res. 2025 Apr 29;74(1):71. doi: 10.1007/s00011-025-02032-5.
10
Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines.新冠疫苗过敏反应自我报告的皮肤症状的发生率及相关因素
Vaccines (Basel). 2025 Mar 10;13(3):289. doi: 10.3390/vaccines13030289.
本文引用的文献
1
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.美国 2020 年 12 月 21 日-2021 年 1 月 10 日期间，在接种 Moderna COVID-19 疫苗第一针后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. doi: 10.15585/mmwr.mm7004e1.
2
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.接种辉瑞-生物科技公司新冠疫苗第一剂后包括过敏反应在内的过敏反应。
JAMA. 2021 Feb 23;325(8):780-781. doi: 10.1001/jama.2021.0600.
3
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.美国免疫实施咨询委员会对使用 Moderna COVID-19 疫苗的临时建议-2020 年 12 月。
MMWR Morb Mortal Wkly Rep. 2021 Jan 1;69(5152):1653-1656. doi: 10.15585/mmwr.mm695152e1.
4
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.免疫实践咨询委员会关于使用辉瑞-BioNTech COVID-19 疫苗的临时建议-美国，2020 年 12 月。
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. doi: 10.15585/mmwr.mm6950e2.
5
Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity - United States, January 26-October 3, 2020.与 COVID-19 相关的超额死亡人数，按年龄、种族和族裔划分 - 美国，2020 年 1 月 26 日至 10 月 3 日。
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1522-1527. doi: 10.15585/mmwr.mm6942e2.
6
Vaccine-associated hypersensitivity.疫苗相关过敏反应。
J Allergy Clin Immunol. 2018 Feb;141(2):463-472. doi: 10.1016/j.jaci.2017.12.971.
7
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).疫苗不良事件报告系统（VAERS）中的安全性监测。
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
8
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.过敏反应：免疫接种安全性数据的病例定义及数据收集、分析与呈现指南
Vaccine. 2007 Aug 1;25(31):5675-84. doi: 10.1016/j.vaccine.2007.02.064. Epub 2007 Mar 12.
Zotero 插件